Amatsi (formerly known as CRID Pharma) and Avogadro will join forces in an effort to provide a broader range of drug development services to their respective pharma and biopharma clients. Together, the companies will have more than 175 staff located in France and the U.S.
By combining their expertise and know-how, the group aims to provide its clients with an increased range of services including: Galenic development, analytical development, bioanalysis, PK-ADME studies, residues, etc., quality control (GLP/GMP), ICH stability studies, clinical supplies manufacturing (sterile/non sterile), packaging, storage and distribution, and regulatory support.
Jean-Pascal Conduzorgues, president of Amatsi, said, “With the support of Avogadro’s team, we can offer a larger range of facilities to our clients, increased development capabilities, as well as a stronger quality assurance framework. Together with André Weil, president of Avogadro and Jean-Pierre Arnaud, chief executive officer, I am very pleased to see our companies bringing together their strengths whilst still maintaining our common values of responsiveness, flexibility and customer service.”